- Home
- BVS vs SABR Comparison
BVS vs SABR Comparison
Compare BVS & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVS | SABR |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 950 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.2M | 811.2M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BVS | SABR |
|---|---|---|
| Price | $13.38 | $1.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $17.60 | $2.11 |
| AVG Volume (30 Days) | 371.8K | ★ 8.1M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 163.46 | ★ 283.56 |
| EPS | ★ 0.52 | N/A |
| Revenue | $568,087,000.00 | ★ $3,866,956,000.00 |
| Revenue This Year | $6.46 | $4.34 |
| Revenue Next Year | $6.74 | $4.16 |
| P/E Ratio | $28.56 | ★ N/A |
| Revenue Growth | N/A | ★ 7.46 |
| 52 Week Low | $6.47 | $0.81 |
| 52 Week High | $15.89 | $2.50 |
Technical Indicators
Market Signals| Indicator | BVS | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 37.54 |
| Support Level | $13.44 | $1.53 |
| Resistance Level | $14.33 | $1.99 |
| Average True Range (ATR) | 0.55 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 19.26 | 35.54 |
Price Performance
Historical ComparisonAbout BVS Bioventus Inc.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The marketplace segment represented 80% of total 2025 revenue and airline technology solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.